Medical Developments International (FRA:M5D) Shares Outstanding (EOP): 112.66 Mil (As of Dec. 2025)


FRA:M5D Medical Developments International Ltd FRA:M5D
32 GF Score
Price €0.20
GF Value €0.35
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medical Developments International Shares Outstanding (EOP)?

Medical Developments International FRA:M5D +1.55% 32 Shares Outstanding (EOP) is 112.66 Mil as of Dec. 2025. GuruFocus rates FRA:M5D with a GF Score™ of 32/100 and a GF Value™ of €0.35 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Medical Developments International's shares outstanding for the quarter that ended in Dec. 2025 was 112.66 Mil.

Medical Developments International's quarterly shares outstanding stayed the same from Jun. 2025 (112.66 Mil) to Dec. 2025 (112.66 Mil).

Medical Developments International's annual shares outstanding increased from Jun. 2024 (88.60 Mil) to Jun. 2025 (112.66 Mil). It means Medical Developments International issued new shares from Jun. 2024 to Jun. 2025 .


Medical Developments International  (FRA:M5D) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Medical Developments International Shares Outstanding (EOP) Related Terms


Medical Developments International Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Medical Developments International's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medical Developments International Shares Outstanding (EOP) Chart

Medical Developments International Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 74.34 74.38 88.60 88.60 112.66

Medical Developments International Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.60 88.60 112.66 112.66 112.66

FRA:M5D vs ZTS: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medical Developments International Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Medical Developments International's Shares Outstanding (EOP) falls into.


FRA:M5D
32GF Score
Medical Developments International Ltd FRA:M5D
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medical Developments International Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 112.66 Mil mean?
Medical Developments International (FRA:M5D) has a Shares Outstanding (EOP) of 112.66 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Medical Developments International and its competitors.
Is Medical Developments International's Shares Outstanding (EOP) too high?
Medical Developments International's current Shares Outstanding (EOP) is 112.66 Mil. Overall, Medical Developments International has a GF Score™ of 32/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's Shares Outstanding (EOP) compare to ZTS?
Medical Developments International's Shares Outstanding (EOP) of 112.66 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Medical Developments International and its competitors. Medical Developments International's current Shares Outstanding (EOP) is 112.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (FRA:M5D) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.35, compared to a current price of €0.20 — trading 43.7% below its estimated fair value. The current Shares Outstanding (EOP) is 112.66 Mil. Medical Developments International's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Medical Developments International (FRA:M5D), the current Shares Outstanding (EOP) is 112.66 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medical Developments International (FRA:M5D) Overvalued in 2026?

Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued. The current stock price of €0.20 is trading 43.7% below its estimated GF Value™ of €0.35. GuruFocus considers Medical Developments International to be Significantly Undervalued.

Key valuation signals for FRA:M5D:

  • Shares Outstanding (EOP): 112.66 Mil
  • GF Value™: €0.35 vs. price of €0.20 (43.7% below fair value)
  • GF Score™: 32/100 with 2 warning signs

No single metric tells the full story. See the FRA:M5D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medical Developments International Business Description

Other Exchanges MDDVF:USAMVP:Australia
Address 4 Caribbean Drive, Scoresby, VIC, AUS, 3179
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
32GF Score

Get the complete analysis for FRA:M5D

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.35
GF Value